Rezdiffra Pregnancy and Lactation Registry

NCT07541469 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2026-04-21

No results posted yet for this study

Summary

To evaluate pregnancy and clinical outcomes in women with NASH and their infants after exposure to Rezdiffra at any time during pregnancy and/or lactation.

Conditions

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Interventions

DRUG

Rezdiffra

Exposure to at least one dose of Resmetirom.

Sponsors & Collaborators

  • Madrigal Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-04
Primary Completion
2030-04-08
Completion
2030-04-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07541469 on ClinicalTrials.gov